The cytokine network in sarcoidosis and its clinical relevance

Journal of Internal Medicine

Volumn 253, Issue 1, 2003, Pages 18-30

  Ziegenhagen, M W ^a   Muller Quernheim J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Alveolitis; Bronchoalveolar lavage; Disease activity; Prognosis; Sarcoidosis; TNF

Indexed keywords

CHIMERIC ANTIBODY; CORTICOSTEROID; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 2;

CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; GENETIC POLYMORPHISM; GENETIC RISK; GRANULOMA; HLA SYSTEM; HUMAN; HYPERCOAGULABILITY; IMMUNOGENETICS; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; LUNG ALVEOLUS MACROPHAGE; MEDIATOR RELEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEROLOGY; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME; TUBERCULOSIS;

CYTOKINES; HUMANS; MACROPHAGES, ALVEOLAR; MAJOR HISTOCOMPATIBILITY COMPLEX; SARCOIDOSIS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037238604     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01074.x     Document Type: Conference Paper

References (101)

1. Müller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998; 12: 716-38.
2. Luisetti M, Beretta A, Casali L. Genetic aspects in sarcoidosis. Eur Respir J 2000; 16: 768-80.
3. Hunninghake GW, Costabel U, Ando M et al. ATS/ERS/WA-SOG statement on sarcoidosis. American Thoracic Society/ European Respiratory Society/World Association of Sarcoi-dosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73.
4. Vestbo J, Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis. Sarcoidosis 1994; 11: 123-5.
5. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52: 525-33.
6. Drent M, van Velzen-Blad H, Diamant M, Hoogsteden HC, van den Bosch JMM. Relationship between presentation of sarcoidosis and T lymphocyte profile. A study in bronchoalveolar lavage fluid. Chest 1993; 104: 795-800.
7. Ward K, O'Connor C, Odlum C, Fitzgerald MX. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 1989; 44: 6-12.
8. Planck A, Eklund A, Grunewald J. Inflammatory BAL-fluid and serum parameters in HLA DR17 positive vs. DR17 negative patients with pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 64-9.
9. Rosenblum GR, Donato NJ. Tumor necrosis factor α: A multifaceted hormone. Crit Rev Immunol 1989; 9: 21-44.
10. Kunkel SL, Chensue SW, Strieter RM, Lynch JP, Remick DG. Cellular and molecular aspects of granulomatous inflammation. Am J Respir Cell Mol Biol 1989; 1: 439-47.
11. Sugarman BJ, Aggarwal BB, Hass PE et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943-5.
12. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987; 329: 630-2.
13. Mornex JF, Leroux C, Greenland T, Ecochard D. From granuloma to fibrosis in interstitial lung disease: molecular and cellular interactions. Eur Respir J 1994; 7: 779-85.
14. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung T-lymphocytes in active pulmonary sarcoidosis. N. Engl. J. Med 1983; 308: 793-800.
15. Müller-Quernheim J, Saltini C, Sondermeyer P, Crystal RG. Compartmentalized activation of the interleukin-2 gene by lung T-lymphocytes in active pulmonary sarcoidosis. J Immunol 1986; 137: 3475-83.
16. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-57.
17. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996; 80: 225-35.
18. Robinson BWS. McLemore T, Crystal RG. γ interferon is spontaneously released by alveolar macrophages and lung T-lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75: 1488-95.
19. Walker C, Bauer W, Braun RK et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994; 150: 1038-48.
20. Bäumer IG, Zissel M, Schlaak, J, Muller-Quernheim J. Th1/ Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1997; 16: 171-7.
21. Manetti R, Parronchi P, Giudizi MG et al. Natural killer cell stimulatory factor (interleukin 12 {Il-12}) induces T helper type 1 (Th1) -specific immune responses and inhibits the development of Il-4-producing Th cells. J Exp Med 1993; 177: 1199-204.
22. Müller-Quernheim J, Pfeifer S, Kienast K, Zissel G. Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis. Lung 1996; 174: 243-53.
23. Lawrence EC, Brousseau KP, Berger MB, Kurman CC, Marcon L, Nelson DL. Elevated concentration of soluble interleukin-2 receptors in serum samples and bronchoalveolar fluids in active sarcoidosis. Am Rev Respir Dis 1988; 137: 759-64.
24. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Müller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-92.
25. Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996; 154: 713-9.
26. Car BD, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 1994; 149: 655-9.
27. Standiford T, Rolfe M, Kunkel S et al. Macrophage inflammatory protein-1 α expression in interstitial lung disease. J Immunol 1993; 151: 2852-63.
28. Homolka J, Müller-Quernheim J. Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis. Lung 1993; 171: 173-83.
29. Moller DR, Forman JD, Liu MC et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156: 4952-60.
30. Cameron LA, Taha RA, Tsicopoulos A et al. Airway epithelium expresses interleukin-18. Eur Respir J 1999; 14: 553-9.
31. Shigehara K, Shijubo N, Ohmichi M et al. Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000; 162: 1979-82.
32. Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Müller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Invest Med 1998; 46: 223-31.
33. Drent M, Jacobs JA, de Vries J, Lamers RJ, Liem I.H, Wouters EF. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 1999; 13: 1338-44.
34. Capelli A, Di Stefano A, Lusuardi M, Gnemmi I, Donner CF. Increased macrophage inflammatory protein-1alpha and macrophage inflammatory protein-1beta levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis. Am J Respir Crit Care Med 2002; 165: 236-41.
35. Hashimoto S, Nakayama T, Gon Y et al. Correlation of plasma monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1alpha (MIP-1alpha) levels with disease activity and clinical course of sarcoidosis. Clin Exp Immunol 1998; 111: 604-10.
36. Iyonaga K, Suga M, Ichiyasu H, Yamamoto T, Hiraga Y, Ando M. Measurement of serum monocyte chemoattractant protein-1 and its clinical application for estimating the activity of granuloma formation in sarcoidosis [see comments]. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 165-72.
37. Kim DS, Jeon YG, Shim TS et al. The value of interleukin-12 as an activity marker of pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 271-6.
38. Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91.
39. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 1996; 173: 230-5.
40. Chensue SW, Otterness IG, Higashi GI, Shmyr Forsch C, Kunkel SL. Monokine production by hypersensitivity (Shistosoma mansoni egg) and foreign body (Sephadex bead) -type granuloma macrophages. Evidence for sequential production of IL-1 and tumor necrosis factor. J Immunol 1989; 142: 1281-6.
41. Kindler V, Sappino A, Grau G, Piguet P, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-40.
42. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-4.
43. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001; 135: 27-31.
44. Begovich AB, Klitz W, Moonsamy PV, Van de Water J, Peltz G, Gershwin ME. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 1994; 43: 71-7.
45. Odum N, Milman N, Jakobsen BK, Georgsen J, Svejgaard A. HLA class II (DR, DQ, DP) in patients with sarcoidosis: evidence of an increased frequency of DRw6. Exp Clin Immuno-genet 1991; 8: 227-32.
46. Lenhart K, Kolek V, Bartova A. HLA antigens associated with sarcoidosis. Dis Markers 1990; 8: 23-9.
47. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997; 156: 1601-5.
48. Schürmann M, Reichel P, Müller-Myhsok B, Schlaak M, Müller-Quernheim J, Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med 2001; 164: 840-6.
49. Schürmann M, Lympany PA, Reichel P et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med 2000; 162: 861-4.
50. Hampe J, Cuthbert A, Croucher PJ et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925-8.
51. Hugot JPP, Laurent C, Gower-Rousseau JM et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1997; 379: 821-3.
52. Tromp G, Kuivaniemi H, Raphael S et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet 1996; 59: 1097-107.
53. Bohnert A, Schurmann M, Hartung A, Hackstein H, Müller-Quernheim J, Bein G. No linkage of the interleukin-4 receptor locus on chromosome 16p11.2-12.1 with sarcoidosis in German multiplex families. Eur J Immunogenet 2002; 29: 269-72.
54. McGuire W, Hill A, Allsopp C, Greenwood B, Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-11.
55. Cabrera M, Shaw MA, Sharples C et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995; 182: 1259-64.
56. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1436-9.
57. Myatt N, Coghill G, Morrison K, Jones D, Cree IA. Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation. J Clin Pathol 1994; 47;423-6.
58. Bergeron A, Bonay M, Kambouchner M et al. Cytokine patterns in tuberculous and sarcoid granulomas: correlations with histopathologic features of the granulomatous response. J Immunol 1997; 159: 3034-43.
59. Müller-Quernheim J, Pfeifer S, Männel D, Strausz J, Ferlinz R. Lung restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis 1992; 145: 187-92.
60. Seitzer U, Swider C, Stüber F et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997; 9: 787-90.
61. Somoskövi A, Zissel G, Seitzer U, Gerdes J, Schlaak M, Müller-Quernheim J. Polymorphism at position-308 in the promotor region of the TNF-alpha and in the first intron o the TNF-beta genes and spontaneous and lipopolysaccharide-induced TNF-alpha release in sarcoidosis. Cytokine 1999; 11: 882-7.
62. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-60.
63. Price P, Witt C, Allcock R et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999; 167: 257-74.
64. Martinetti M, Tinelli C, Kolek V et al. 'The sarcoidosis map'. A joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152: 557-64.
65. Swider C, Schnittger L, Bogunia-Kubik K et al. TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. Eur Cytokine Netw 1999; 10: 143-6.
66. Seitzer UJ, Gerdes, Müller-Quernheim J. Evidence for disease phenotype associated haplotypes (DR.TNF) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 279-83.
67. Grutters JC, Sato H, Pantelidis P et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002; 165: 1119-24.
68. Grunewald J, Eklund A. Human leukocyte antigen genes may outweigh racial background when generating a specific immune response in sarcoidosis PG - 1046-8. Eur Respir J 2001; 17: 1046-8.
69. Yamaguchi E, Itoh A, Hizawa N, Kawakami Y. The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis. Chest 2001; 119: 753-61.
70. Takashige N, Naruse TK, Matsumori A et al. Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens 1999; 54: 191-3.
71. Bachwich PR, Lynch JP III, Larrick J, Spengler M, Kunkel SL. Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol 1986; 125: 421-5.
72. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115: 36-42.
73. Kunkel SL, Remick DG, Strieter RM, Larrick JW. Mechanisms that regulate the production and effects oftumor necrosis factor-α. Crit Rev Immunol 1989; 9: 93-117.
74. Beutler B, Greenwald D, Hulmes JD et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316: 552-4.
75. Foley N, Lambert C, McNicol M, Johnson N, Rook GAW. An inhibitor of the toxicity of tumor necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease. Clin Exp Immunol 1990; 80: 395-9.
76. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87: 3127-31.
77. Abdolrasulnia R, Shepherd VL. Purification of type I and type II tumor necrosis factor receptors from human lung tissue. Am J Respir Cell Mol Biol 1992; 7: 42-8.
78. Hino T, Nakamura H, Shibata Y, Abe S, Kato S, Tomoike H. Elevated levels of type II soluble tumor necrosis factor receptors in the bronchoalveolar lavage fluids of patients with sarcoidosis. Lung 1997; 175: 187-93.
79. Nakayama T, Hashimoto S, Amemiya E, Horie T. Elevation of plasma-soluble tumour necrosis factor receptors (TNF-R) in sarcoidosis. Clin Exp Immunol 1996; 104: 318-24.
80. Ziegenhagen MW, Fitschen J, Martinet N, Schlaak M, Müller-Quernheim J. Serum level of soluble tumour necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J Intern Med 2000; 248: 33-41.
81. Eklund A, Blaschke E. Elevated serum neopterin in sarcoido-sis. Lung 1986; 164: 325-32.
82. Homolka J, Lorenz J, Zuchhold HD, Müller-Quernheim J. Evaluation of soluble CD14 and serum neopterin as serum parameters of inflammatory activity of pulmonary sarcoidosis. Clin Investig 1992; 70: 909-16.
83. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990; 142: 1268-71.
84. Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-22.
85. Ziegenhagen MW, Rothe ME, Zissel G, Müller-Quernheim J. Exaggerated TNF-alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 185-90.
86. Strausz J, Männel D, Pfeifer S, Borkowski A, Ferlinz R, Müller-Quernheim J. Spontaneous monokine release by alveolar macrophages in chronic sarcoidosis. Int Archs Allergy appl Immun 1991; 96: 68-75.
87. Franchimont D, Martens H, Hagelstein MT et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999; 84: 2834-9.
88. Han J, Thompson P, Beutler B. Dexamethasone and pen-toxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-4.
89. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999; 159: 508-11.
90. Moller DR, Wysocka M, Greenlee BM et al. Inhibition of human interleukin-12 production by pentoxifylline. Immunology 1997; 91: 197-203.
91. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-9.
92. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
93. Moller DR, Wysocka M, Greenlee BM et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 5157-61.
94. Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw RJ. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997; 91: 31-9.
95. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-9.
96. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998; 39: 835-8.
97. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002; 122: 227-32.
98. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
99. van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
100. Alabi OF, Lower EE, Baughman RP. Use of Infliximab in refractory sarcoidosis. Am J Respir Crit Care Med 2001; 163: A557.
101. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.